Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 2,770 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: One cycle Clear all
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Recurrent or Progressive Glioma

NCT00337207
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multiple CoolSculpting Treatment Study

NCT01814007
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq CoolSculpting System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Pleasanton, California • Walnut Creek, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 28, 2026, 8:21 PM EDT
Active, not recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

NCT02574728
View directory record Official record
Conditions
Cancer
Interventions
Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT04231747
View directory record Official record
Conditions
Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL)
Interventions
CC-97540
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 28, 2026, 8:21 PM EDT
Not listed Phase 3 Interventional

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

NCT02584478
View directory record Official record
Conditions
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Interventions
AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
8
States / cities
Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

De-Escalation Therapy for Human Papillomavirus Negative Disease

NCT03944915
View directory record Official record
Conditions
Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
Carboplatin, Paclitaxel, Nivolumab, Radiation, Hydroxyurea Pill, 5-fluorouracil, Filgrastim Injection, Cisplatin
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Lerapolturev in Recurrent Malignant Glioma

NCT02986178
View directory record Official record
Conditions
Malignant Glioma
Interventions
lerapolturev, Lomustine
Biological · Drug
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 28, 2026, 8:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126
View directory record Official record
Conditions
NSCLC
Interventions
EP0031, Platinum chemotherapy, Pemetrexed
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Steroids and Pain Control After Tonsillectomy

NCT03995628
View directory record Official record
Conditions
Tonsillitis, Obstructive Sleep Apnea of Child
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Passive Limb Movement Study

NCT05935670
View directory record Official record
Conditions
Stroke, Vascular Diseases, Ischemic
Interventions
Ischemic Conditioning
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

NCT01017731
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
IMC-1121B, Moxifloxacin, Diphenhydramine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Atlanta, Georgia • Metairie, Louisiana • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 28, 2026, 8:21 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
342
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome

NCT01112683
View directory record Official record
Conditions
Down Syndrome
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 32 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 28, 2026, 8:21 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pilot Studies Blocking Injury-Induced MVP Release in Skin Using Topical Amitriptyline

NCT07716722
View directory record Official record
Conditions
Thermal Burn, Amitriptyline
Interventions
Amitriptyline, Placebo
Drug · Other
Lead sponsor
Wright State University
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Effect of Milnacipran in Patients With Fibromyalgia

NCT01108731
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

NCT00987480
View directory record Official record
Conditions
Aplastic Anemia, Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine., CliniMACS device
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

NCT02819024
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Dexamethasone, Device for PET, Laboratory Biomarker Analysis, Positron Emission Tomography
Drug · Device · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

NCT00217282
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
oxaliplatin, gemcitabine, bevacizumab
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 28, 2026, 8:21 PM EDT
Completed No phase listed Observational

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

NCT02844400
View directory record Official record
Conditions
Malignant Solid Tumor, Hematologic Malignancies
Interventions
Biometric Devices, Physical Performance Testing
Device · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

NCT02817841
View directory record Official record
Conditions
Contraception
Interventions
15 mg E4/3 mg DRSP
Drug
Lead sponsor
Estetra
Industry
Eligibility
16 Years to 50 Years · Female only
Enrollment
2,148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 28, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

NCT00513383
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Panitumumab, Carboplatin, Paclitaxel, Intensity Modulated Radiation Therapy, 5-Fluorouracil, Docetaxel, Cisplatin
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 28, 2026, 8:21 PM EDT